FDA Lifts the Black Box on Menopause Hormone Therapy After 21 Years
On November 10, 2025, the U.S. Department of Health and Human Services and the FDA formally initiated the removal of black box warnings from all hormone replacement therapy products containing estrogen. Labels warning of cardiovascular disease, breast cancer, and dementia risk now have six months to be updated.
A black box warning is the strongest safety label the FDA places on a pharmaceutical product. Removing one after 21 years is not a label edit. It is a correction of how medicine has been interpreting menopause care since 2002.
The Shadow of the 2002 WHI Study
The fear surrounding hormone therapy traces back to a single announcement. In 2002, the National Institutes of Health halted the estrogen-plus-progestin arm of the Women’s Health Initiative (WHI) trial early, citing elevated risks of breast cancer, heart attack, and stroke. News coverage was immediate and sweeping. Within months, millions of women stopped their prescriptions.
The problem was one of study design. The average age of WHI participants was 63. Most had been postmenopausal for more than a decade before starting hormone therapy. Vascular aging and atherosclerosis were already underway. The results of giving hormones to women in their sixties were then used to issue warnings that applied to women in their early fifties, at the onset of menopause, for whom the biology was entirely different.
Researchers called this the timing hypothesis, or the window of opportunity. Estrogen’s cardiovascular and metabolic benefits depend on when treatment begins. Starting early, when blood vessels retain elasticity, produces different outcomes than starting late.
Two Decades of Evidence That Changed the Picture
Research continued even as prescriptions fell. The FDA’s November 2025 decision reflects two bodies of accumulated evidence.
The 10-year window: Women who begin HRT within 10 years of menopause onset or before age 60 show cardiovascular protection rather than harm. Estrogen supports vascular elasticity, reduces LDL cholesterol, and suppresses vascular inflammation. Re-analysis of WHI data confirmed that the 50-to-59 age subgroup showed lower, not higher, rates of coronary artery disease. The benefit window is real, and timing is everything.
Transdermal formulations and their distinct risk profile: Oral estrogen passes through the liver before entering systemic circulation. This hepatic first-pass metabolism increases production of clotting factors, raising the risk of deep vein thrombosis and stroke. Transdermal patches and gels deliver estrogen directly into the bloodstream through the skin, bypassing hepatic metabolism entirely. Large European cohort studies report that transdermal estrogen carries substantially lower thrombotic risk than oral forms. The new FDA labeling explicitly acknowledges that risk differs by delivery route.
On breast cancer, estrogen-only therapy (prescribed after hysterectomy) is associated with lower breast cancer incidence in long-term data. Combination estrogen-progestogen therapy carries a modest increase in absolute breast cancer risk with use beyond five years, a risk that persists in the evidence base and is not dismissed in the new labeling. The change is that this risk is now placed in context alongside documented benefits rather than listed alone as a headline warning.
What the FDA Accepted, and What It Did Not
This is not a wholesale removal of all HRT warnings. The FDA drew a deliberate line.
Removed: Black box warnings for cardiovascular disease, breast cancer, and dementia. The updated labeling states that for women beginning HRT within 10 years of menopause onset, long-term benefits are possible.
Retained: The endometrial cancer warning on estrogen-only products remains in place. This applies to women with an intact uterus who take estrogen without progestogen. The evidence here is well-established and unaffected by the timing-hypothesis literature. Combined therapy with progestogen remains standard for women who have not had a hysterectomy.
Label changes are due within six months of the November announcement, placing the deadline around May 2026.
What This Means in the Clinic
For women with moderate to severe vasomotor symptoms, genitourinary syndrome of menopause, or elevated osteoporosis risk, the timing window matters. The decades immediately following menopause onset represent the period when HRT’s benefits are largest and its risks lowest. That relationship inverts with age and time elapsed since menopause.
Transdermal delivery is worth discussing explicitly with a physician, particularly for women with personal or family history of thrombotic events. The formulation choice is not trivial.
For women who cannot or prefer not to use hormones, the landscape has also changed. Fezolinetant (Veozah), approved by the FDA in 2023, blocks NK3 receptors in the hypothalamus that drive vasomotor symptoms without any estrogenic mechanism. Elinzanetant (Lynkuet) extends this class in Europe. Clinical trial data shows 50 to 60 percent reductions in hot flash frequency from these agents. Non-hormonal options are no longer a compromise, but a genuine clinical category.
What This Decision Actually Does
The FDA is not recommending that all menopausal women start HRT. It is correcting a warning built on a misreading of a single study, applied to a population that study was not designed to represent.
For 21 years, that black box sat at the start of every conversation between a patient and a physician. A woman asking whether HRT was right for her encountered a cardiovascular warning before anything else. That framing shaped what questions got asked, and which prescriptions got written.
Removing it does not answer the question for any individual woman. What it does is allow that conversation to begin without a distortion that should not have been there in the first place.
Q. Does removing the black box warning mean HRT is now safe for everyone?
The FDA action corrects a warning that misapplied the 2002 WHI study data to women it was never designed to cover. For women who start HRT within 10 years of menopause onset or before age 60, cumulative evidence supports long-term benefits that can outweigh risks. The endometrial cancer warning on estrogen-only products remains. Individual risk profiles and symptoms should guide the decision in consultation with a physician.
Q. What is the difference between a transdermal patch and an oral pill?
Oral estrogen is absorbed through the gut and metabolized by the liver, which can trigger clotting-related protein changes that elevate DVT and stroke risk. Transdermal patches deliver estrogen directly into the bloodstream through the skin, bypassing hepatic first-pass metabolism. Multiple cohort studies report significantly lower thrombotic risk with transdermal versus oral formulations. The delivery route meaningfully shapes the risk profile.
Q. Do women with and without a uterus need different prescriptions?
Women without a uterus can use estrogen-only therapy, and the endometrial cancer warning does not apply to them. Women with an intact uterus require a progestogen added to estrogen, because unopposed estrogen can cause endometrial hyperplasia. Whether progestogen is included affects both the prescription design and the long-term risk profile substantially.